Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution

Research output: Contribution to journalArticle

Abstract

Purpose: To describe outcomes of Electrochemotherapy as palliative treatment in patients with advanced head and neck (H&N) tumours. Methods: Ninety-three patients (120 treatment sessions) with H&N recurrent and/or metastatic neoplasm were treated. Treatment response was assessed 4 weeks after ECT with clinical examination and two months after the first evaluation with a CT scan of the H&N for deep lesions evaluation. The grade of bleeding and pain before, at the end of treatment and one week after ECT were evaluated. Results: Five percent of complete responses, 40% of partial responses were registered. Disease progression was seen in 20% of patients after the first ECT procedure, the remaining 34% of patients experienced stable disease. A good control of pain and bleeding was obtained, especially in patients with moderate symptoms before the treatment. No toxicities related to ECT were seen. Conclusions: ECT is an interesting antitumoral therapy in advanced chemo and radio-refractory H&N neoplasms. ECT is able to reduce frequent symptoms, such as pain and bleeding, improving quality of life without damage to healthy tissue and with limited side effects. Moreover, ECT reduces hospitalization time and may contribute to an overall reduction in healthcare costs associated with advanced H&N cancers care.

Original languageEnglish
Pages (from-to)77-84
Number of pages8
JournalOral Oncology
Volume92
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Electrochemotherapy
Palliative Care
Neck
Head
Neoplasms
Hemorrhage
Pain
Therapeutics
Radio
Health Care Costs
Disease Progression
Hospitalization
Quality of Life

Keywords

  • Advanced head and neck cancer
  • Bleeding control
  • Electrochemotherapy
  • Pain
  • Palliative setting
  • Quality of life

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

@article{e28900a5efb249cb9e8baea7aa44d817,
title = "Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution",
abstract = "Purpose: To describe outcomes of Electrochemotherapy as palliative treatment in patients with advanced head and neck (H&N) tumours. Methods: Ninety-three patients (120 treatment sessions) with H&N recurrent and/or metastatic neoplasm were treated. Treatment response was assessed 4 weeks after ECT with clinical examination and two months after the first evaluation with a CT scan of the H&N for deep lesions evaluation. The grade of bleeding and pain before, at the end of treatment and one week after ECT were evaluated. Results: Five percent of complete responses, 40{\%} of partial responses were registered. Disease progression was seen in 20{\%} of patients after the first ECT procedure, the remaining 34{\%} of patients experienced stable disease. A good control of pain and bleeding was obtained, especially in patients with moderate symptoms before the treatment. No toxicities related to ECT were seen. Conclusions: ECT is an interesting antitumoral therapy in advanced chemo and radio-refractory H&N neoplasms. ECT is able to reduce frequent symptoms, such as pain and bleeding, improving quality of life without damage to healthy tissue and with limited side effects. Moreover, ECT reduces hospitalization time and may contribute to an overall reduction in healthcare costs associated with advanced H&N cancers care.",
keywords = "Advanced head and neck cancer, Bleeding control, Electrochemotherapy, Pain, Palliative setting, Quality of life",
author = "Francesco Longo and Francesco Perri and Ettore Pavone and Corrado Aversa and Maglione, {Maria Grazia} and Agostino Guida and Massimo Montano and Salvatore Villano and Antonio Daponte and Francesco Caponigro and Franco Ionna",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.oraloncology.2019.03.016",
language = "English",
volume = "92",
pages = "77--84",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours

T2 - Outcome analysis in 93 patients treated in a single institution

AU - Longo, Francesco

AU - Perri, Francesco

AU - Pavone, Ettore

AU - Aversa, Corrado

AU - Maglione, Maria Grazia

AU - Guida, Agostino

AU - Montano, Massimo

AU - Villano, Salvatore

AU - Daponte, Antonio

AU - Caponigro, Francesco

AU - Ionna, Franco

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose: To describe outcomes of Electrochemotherapy as palliative treatment in patients with advanced head and neck (H&N) tumours. Methods: Ninety-three patients (120 treatment sessions) with H&N recurrent and/or metastatic neoplasm were treated. Treatment response was assessed 4 weeks after ECT with clinical examination and two months after the first evaluation with a CT scan of the H&N for deep lesions evaluation. The grade of bleeding and pain before, at the end of treatment and one week after ECT were evaluated. Results: Five percent of complete responses, 40% of partial responses were registered. Disease progression was seen in 20% of patients after the first ECT procedure, the remaining 34% of patients experienced stable disease. A good control of pain and bleeding was obtained, especially in patients with moderate symptoms before the treatment. No toxicities related to ECT were seen. Conclusions: ECT is an interesting antitumoral therapy in advanced chemo and radio-refractory H&N neoplasms. ECT is able to reduce frequent symptoms, such as pain and bleeding, improving quality of life without damage to healthy tissue and with limited side effects. Moreover, ECT reduces hospitalization time and may contribute to an overall reduction in healthcare costs associated with advanced H&N cancers care.

AB - Purpose: To describe outcomes of Electrochemotherapy as palliative treatment in patients with advanced head and neck (H&N) tumours. Methods: Ninety-three patients (120 treatment sessions) with H&N recurrent and/or metastatic neoplasm were treated. Treatment response was assessed 4 weeks after ECT with clinical examination and two months after the first evaluation with a CT scan of the H&N for deep lesions evaluation. The grade of bleeding and pain before, at the end of treatment and one week after ECT were evaluated. Results: Five percent of complete responses, 40% of partial responses were registered. Disease progression was seen in 20% of patients after the first ECT procedure, the remaining 34% of patients experienced stable disease. A good control of pain and bleeding was obtained, especially in patients with moderate symptoms before the treatment. No toxicities related to ECT were seen. Conclusions: ECT is an interesting antitumoral therapy in advanced chemo and radio-refractory H&N neoplasms. ECT is able to reduce frequent symptoms, such as pain and bleeding, improving quality of life without damage to healthy tissue and with limited side effects. Moreover, ECT reduces hospitalization time and may contribute to an overall reduction in healthcare costs associated with advanced H&N cancers care.

KW - Advanced head and neck cancer

KW - Bleeding control

KW - Electrochemotherapy

KW - Pain

KW - Palliative setting

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85063526194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063526194&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2019.03.016

DO - 10.1016/j.oraloncology.2019.03.016

M3 - Article

AN - SCOPUS:85063526194

VL - 92

SP - 77

EP - 84

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -